share_log

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharmaceuticals | 8-K:Shuttle Pharma通過獨家許可協議推進前列腺癌預測生物標誌物計劃
SEC announcement ·  2023/10/30 17:14
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息